ArticleEuropean journal of nuclear medicine and molecular imaging2022
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 96 citations in OpenAlex.
- Deep learning-based PSMA PET segmentation repeatability: A post-hoc analysis of a single-center, prospective, test-retest trial.La Radiologia medica · 2026Trial
- Chrónos and Káiros in theragnostics: re-assessing time toxicity in final-line radiopharmaceutical treatments.European journal of nuclear medicine and molecular imaging · 2026Article
- The Prognostic Value ofAnnals of nuclear medicine · 2026Article
- PSMA-PET response under [European journal of nuclear medicine and molecular imaging · 2026Article
- Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts.Oncology and therapy · 2026Review
- ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer.European radiology · 2026Review
- RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- coPERCIST: AI-assisted PET-CT response assessment.European journal of nuclear medicine and molecular imaging · 2026Article
- Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617.European journal of nuclear medicine and molecular imaging · 2026Article
- PSMA PET-directed radiotherapy for prostate cancer: From precision planning to future innovations.View (Beijing, China) · 2026Article
- Actinium-225-PSMA versus lutetium-177-PSMA radioligand therapy for metastatic castration-resistant prostate cancer: results of an observational study.Frontiers in oncology · 2026Article
- FDG/PSMA discordance in [Frontiers in oncology · 2026Review
- PSMA PET/CT for prostate cancer diagnosis: current applications and future directions.Journal of cancer research and clinical oncology · 2025Review
- Integrating Prostate Specific Membrane Antigen-PET into Clinical Practice for Prostate Cancer.PET clinics · 2025Review
- RECIP 1.0 + PSA for response assessment in mCRPC patients treated withEJNMMI research · 2025Article
- [Role of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) in staging].Urologie (Heidelberg, Germany) · 2025Review
- Evaluating response to radium-223 usingAnnals of nuclear medicine · 2025Article
- Article
- Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview.Biomedicines · 2024Review
- Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?Annals of nuclear medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, the adapted Prostate Cancer Working Group Criteria 3 (aPCWG3), the adapted Positron Emission Tomography Response Criteria in Solid Tumors (aPERCIST), the PSMA PET Progression (PPP), and the Response Evaluation Criteria In PSMA-Imaging (RECIP) 1.0 for response evaluation using prostate-specific membrane antigen (PSMA)-PET/CT in men with metastatic castration-resistant prostate cancer (mCRPC) treated with
methodsA total of 124 patients were included in this multicenter retrospective study. All patients received
resultsA total of 43 (35%) of patients had non-measurable disease according to RECIST 1.1. Sixteen (13%), 66 (52%), 72 (58%), 69 (56%), and 39 (32%) of 124 patients had PD according to RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP, respectively. PD vs no-PD had significantly higher risk of death according to aPCWG3 (HR = 2.37; 95%CI, 1.62-3.48; p < 0.001), aPERCIST (HR = 2.48; 95%CI, 1.68-3.66; p < 0.001), PPP (HR = 2.72; 95%CI, 1.85-4.01; p < 0.001), RECIP 1.0 (HR = 4.33; 95%CI, 2.80-6.70; p < 0.001), but not according to RECIST 1.1 (HR = 1.29; 95%CI, 0.73-2.27; p = 0.38). The κ index of RECIST 1.1, aPCWG3, aPERCIST 1.0, PPP, and RECIP 1.0 for identifying PD vs no-PD were 0.50 (95%CI, 0.32-0.76), 0.72 (95%CI, 0.63-0.82), 0.68 (95%CI, 0.63-0.73), 0.73 (95%CI, 0.63-0.83), and 0.83 (95%CI, 0.77-0.88), respectively.
conclusionPSMA-PET-specific criteria for early response evaluation in men with mCRPC treated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.